MIR106A: A Potential Drug Target and Biomarker (G406899)
MIR106A: A Potential Drug Target and Biomarker
Mir106a, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and diverse functions have piqued the interest of researchers, and recent studies have shed light on its potential role in these diseases.
MIR106a is a microRNA (miRNA), a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation. It is expressed in various cell types and has been shown to regulate gene expression in response to various environmental and cellular factors . MIR106a has been identified in various organisms, including humans, and its function and structure have been studied extensively.
One of the defining features of MIR106a is its unique structure. It is a single-stranded RNA molecule that contains a conserved core of 19 amino acids. The core is surrounded by a variable region, which includes a hypervariable region (HVR) and a stem -loop region. The HVR is a loop of 14 amino acids that is involved in the formation of a stable interaction with a protein called SIS, which is a key regulator of gene expression.
The stem-loop region is a structural element that is involved in the regulation of microRNA stability and translation efficiency. It consists of a series of alternating G/C and A/T base pairs that create a stable stem-loop structure. This region has has been shown to play a critical role in the regulation of miRNA stability and translation efficiency.
MIR106a has been shown to regulate a wide range of genes, including coding and non-coding RNA molecules. It has been shown to regulate gene expression in response to various environmental and cellular factors, including changes in gene expression levels, cell cycle progression, and cellular stress.
One of the most promising aspects of MIR106a is its potential as a drug target. Its unique structure and diverse functions make it an attractive target for small molecules, antibodies, or other therapeutic agents. Several studies have shown that MIR106a is a promising drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In cancer, MIR106a has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. It has been shown to promote the growth and survival of cancer cells, and to inhibit the efficacy of anti-cancer drugs. Several studies have shown that MIR106a can be targeted with small molecules, antibodies, or other therapeutic agents that can inhibit its function or activity.
In neurodegenerative diseases, MIR106a has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of stress response. It has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
In autoimmune disorders, MIR106a has been shown to be involved in the regulation of immune response and inflammation. It has been shown to contribute to the development and maintenance of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.
MIR106a is also a potential biomarker for various diseases. Its unique structure and diverse functions make it an attractive target for diagnostic tools, including qRT-PCR, RNA sequencing, and microarray analysis. Several studies have shown that MIR106a can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In conclusion, MIR106a is a unique and promising molecule that has captured the interest of researchers due to its unique structure and diverse functions. Its potential as a drug target and biomarker make it an attractive target for small molecules, antibodies, or other therapeutic agents that can
Protein Name: MicroRNA 106a
The "MIR106A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR106A comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278
